MedTrace Logo

A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors

NCT06771921 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2026-01-30

No results posted yet for this study

Summary

The purpose of this trial is to measure the following in participants with solid cancers who receive GEN1078.

* The side effects seen with GEN1078
* What the body does with GEN1078 once it is administered
* What GEN1078 does to the body once it is administered
* How well GEN1078 works against advanced solid tumors

Trial details include:

* The estimated trial duration is 8 months for an individual participant (the trial duration may vary for each participant).
* The treatment duration will be an estimated 3-month treatment period (the duration of treatment may vary for each participant).
* The visit frequency will be daily or visits every few days for the first few months.

All participants will receive active drug; no one will be given placebo.

Conditions

  • Malignant Solid Tumor

Interventions

DRUG

GEN1078

Specified dose on specified days.

Sponsors & Collaborators

  • Genmab

    lead INDUSTRY

Principal Investigators

  • Study Official · Genmab

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-29
Primary Completion
2025-06-11
Completion
2025-06-11

Countries

  • Denmark
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06771921 on ClinicalTrials.gov